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Figure 2. Time course of the 19F SNR in enhanced regions 
where plaque was confirmed through histology. After an 
initial SNR increase, there is no significant change after 
day 6, which suggests that this may be the optimal day of 
observation. 
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Introduction 
The non-invasive characterization of atherosclerotic plaque is of great clinical interest since quantitative anatomical changes of both the coronary lumen and vessel wall 
measured with invasive methods (x-ray coronary angiography and intravascular ultrasound (IVUS)) have recently been established as insufficient predictors of sites that 
are prone to plaque rupture [1]. Several advanced molecular imaging methodologies have been developed over recent years to better characterize atherosclerosis non-
invasively [2,3], but some of these promising techniques suffer from the disadvantage that the specific contrast agents are not (yet) approved for human use. One of the 
strategies that have successfully been used to visualize inflammation, which has been linked to plaque vulnerability [4], consists of the intravenous injection of a 
contrast agent that is partially absorbed by monocytes that infiltrate atherosclerotic plaques. This strategy can also be pursued using an intravenous administration of an 
emulsion of perfluorocarbons, which have already successfully been used to label other inflammation sites [5,6]. Perfluorocarbons are inert, non-toxic carbohydrates 
where the hydrogen has been replaced with fluorine, and of which several types are in phase 3 FDA trials [7]. Fluorine (19F) MRI has 85% of the sensitivity of 1H MRI 
but affords the additional advantage of not having a natural abundance in the body. Therefore, any detected 19F signal is attributable to exogenous sources. The goal of 
this study was therefore to quantify the 19F MR signal as a function of time after injection in atherosclerotic mice and in regions where atherosclerosis commonly occurs. 
Materials and Methods 
The animal studies were approved by the local animal ethics committee. Six apolipoprotein-E-knockout (ApoE) mice received a high-fat diet for 12 weeks to exacerbate 
atherosclerosis development. Every 3 days during the weeks 10-12, four animals received 100-µl tail-vein injections of a 10% perfluoro-15-crown-5-ether (PCE) 
emulsion, which was prepared as previously described [5]. After the 12 weeks, the animals received a large PCE emulsion injection of 750 µl. MR imaging of these 
mice was performed 2, 4, 6, 8 and 14 days after this last injection. All MR experiments were performed on a Varian 9.4 T horizontal bore animal spectrometer in 
combination with a custom-built 18 mm diameter quadrature surface coil that is tunable to both 1H and 19F. Animals were anesthetized with isoflurane (which has a 19F 
signal with a ~3000Hz frequency shift), positioned prone on top of the coil in a dedicated holder. Next, ECG-triggered 1H gradient echo (GRE) images (128x128 matrix, 
field of view 30x30x1.5 mm3, 6 slices, 4 averages) were acquired at the level of the heart. After tuning the coil to 19F, this was followed by non-triggered multi-slice 19F 
turbo spin echo (TSE) imaging (64x64 matrix, TR/TE=1250/4.2ms, echo train length 16, 360 averages, acquisition time 5 min/slice) at the same anatomical level. The 2 
animals that did not receive the PCE emulsion injections were subjected to the same imaging protocol to study the concomitant enhancement of isoflurane. All 19F 
images were interpolated and 
postprocessed with a Gaussian filter, 
after which they were thresholded and 
overlaid on the 1H images. Small patches 
of 19F signal that coregistered 
anatomically the aortic valves or large 
arteries were analyzed. Due to the small 
size of these regions of enhancement, the 
signal-to-noise ratio (SNR) was defined 
in the unprocessed 19F images as the 
maximum pixel intensity divided by the 
standard deviation of the signal of a large 
noise region outside the mouse. This 
analysis was repeated for all animals and 
all time-points. Unpaired two-tailed 
Student’s t-tests were used to assess if 
there was a significant change in 19F SNR 
over time. After MRI, the animals were 
sacrificed and Movat’s pentachrome 
staining of the aortic valve was 
performed for gold-standard comparison. 
On histology blue refers to ground 
substance, blue-black to nuclei and 
elastic fibers, red to muscle, intense red 
to fibrin and green-yellow to collagen 
and reticulin fibers. 
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Figure 1. 19F imaging in a mouse model of atherosclerosis. a) Sagittal anatomical 1H image through the heart and liver of 
a mouse; a carotid artery is also visible. b) Unprocessed 19F image at the same location at day 6 with a dominant signal 
from the liver and small signal from the carotid (dotted arrow). c) Processed fusion image of a and b, showing a clear 
colocalization of the 19F enhancement and the carotid artery. d) Sagittal fusion image at day 6 in another animal, showing 
a significant but weak signal at the level of the aortic valve. e) Fusion image at day 8, showing a clear signal in the heart 
at the location of the aortic valve as well as shifted signals from the subcutaneous fat in the anterior chest. f) Movat’s 
pentachrome staining of the aortic valve, showing significant plaque formation in different stages (arrows). 
Results and Discussion  
19F signal enhancement was observed in regions where atherosclerotic plaques commonly occur such as the
aortic valves, aortic arch and carotids (Fig. 1a-e). Histology of the aortic valves further confirmed the
presence of intermediate and advanced plaque at the locations of the 19F signal, consistent with the disease
model (Fig. 1f). Significant PCE signal was furthermore observed in several repositories of immune cells,
such as the liver (Kupffer cells), lymph nodes and spinal cord. Signal was also observed in the
subcutaneous fat, but the images of the 2 mice that did not receive PCE injections (but in whom histology
showed plaque) confirmed that this was isoflurane, which accumulates exclusively in subcataneous fat. The
quantitative analysis of the SNR of regions where plaque was confirmed through histology showed that a
maximum of ~9 is found at 6 days after the large injection, after which it did not significantly change for 8
more days (Fig. 2). We therefore conclude that non-invasive 19F MR imaging of atherosclerotic plaque may
be feasible while a direct pathway for translation to the human setting exists. 
References 
1.  Stone et al., N Eng J Med 364:p226 (2011) 2. Korosoglou et al., J Am Coll Card 52:p483 (2008)  
3. Makowski et al., Nat Med 17:p383 (2011) 4. Libby, Circulation 104:p365 (2001) 5. Flögel et al., Circ 
118:p140 (2008) 6. Waters et al., J Card Magn Reson 10:p43 (2008) 7. Winslow, Vox Sang 91:p102 (2006)
3945Proc. Intl. Soc. Mag. Reson. Med. 20 (2012)
